Pneuma Respiratory, Inc.

Pneuma Respiratory, Inc. focuses on developing innovative MedTech solutions aimed at mitigating health risks associated with smoking and lung diseases through advanced aerosol delivery technologies. Founded in 2015 and headquartered in Boone, US, Pneuma Respiratory, Inc. specializes in innovative respiratory technology.

The company has secured a total of USD 10. 00 mn in funding, including a notable round in August 2018. Linda Martinez is the founder, and Eric Hunter serves as CEO. Pneuma Respiratory specializes in innovative MedTech products designed to address the health risks associated with smoking and lung diseases.

The company’s core offerings include a water-based aerosol delivery technology that revolutionizes how drugs are administered, focusing on the elimination of harmful toxins found in traditional inhaled nicotine products. Their non-heated nicotine delivery solutions support smoking cessation efforts, while their advanced aerosol technology delivers biologics targeting conditions such as Chronic Obstructive Pulmonary Disease (COPD) and Non-Small Cell Lung Cancer (NSCLC). Pneuma's products are designed for end users seeking safer alternatives to smoking, including smokers aiming for cessation and patients with lung disorders, targeting markets in North America, Europe, and select regions in Asia where smoking-related health issues are prevalent. Pneuma Respiratory’s revenue model primarily involves direct-to-consumer sales and potential partnerships with healthcare providers and pharmaceutical firms.

The company engages directly with consumers and healthcare professionals, facilitating access to their innovative inhaled drug delivery systems. Products may be offered through subscription models or one-time purchases, aligned with regulatory frameworks and market demand. Specific pricing plans and flagship products are proprietary and managed through direct client engagements, enhancing user experience and encouraging adherence to therapy. Pneuma Respiratory intends to leverage its recent funding of USD 10.

00 mn raised in August 2018 to accelerate the development of new products aimed at enhancing inhaled drug delivery. The company plans to expand into additional geographic markets in Europe and Asia by 2023, with a focus on regions significantly impacted by smoking-related health issues. These strategies are designed to bolster Pneuma's portfolio and increase its market presence.